THE DAILY DEAL REPORTS ROBUST DEAL ACTIVITY IN HEALTHCARE SECTORS

Issue marks the second 40-page paper in The Daily Deal's history, buoyed by ads and debut of Johnnie Walker advertising campaign

November 16, 2001--New York, N.Y.--The Daily Deal, (www.TheDeal.com) today examines the dynamic, yet complicated, dealmaking activity that is shaping key healthcare sectors and providing dealmakers and investors with renewed enthusiasm.

"Interest in both biotech and pharmaceuticals has continued as the dot-coms have collapsed. Both fields have been buoyed by scientific excitement, the convergence of molecular biology and information technology and public events, notably bioterrorism," writes Robert Teitelman, editor in chief of The Daily Deal in his introduction, "The new age of wonder?" Teitelman, an expert on healthcare dealmaking and author of two books on the business of biotechnology, sees an industry scrambling to convert recent scientific advances into viable business models, such as the human genome project.

Reporter Kevin DeGeeter, who was a healthcare analyst before taking it on as his beat at The Daily Deal, contributes three of the five articles carried in the report. "Breaking the mold?" presents a case study of Millennium Pharmaceuticals Inc., a biotech startup. "Going to contract" finds that demand and funding for companies that sort and analyze biological data has sprung from undertakings such as the Human Genome Project. Lastly, in "Recession insurance," DeGeeter examines the outlook for managed care, which was referred to in the 1980's as the ultimate healthcare business solution, but is now experiencing its first prolonged economic downturn.

Senior writer Katharine Goncharoff provides further insight into biotechnology dealmaking through a Q&A with M. James Barrett, a healthcare analyst for New Enterprise Associates, a venture capital enterprise.

Reporter Katie Anderson examines a stalwart player from biotechnology's infancy as an industry sector in "Biogen: a survivor's tale." Anderson notes, "The intellectual property developed in those early days still provides the basis for most of Biogen's revenues."

Biotech tables and data were provided by Ernst & Young, including a survival index, comparing and ranking prominent biotechnology companies by cash-on-hand, and a chart comparing the industry as a whole against sector giants.

Today's issue marks the second time that The Daily Deal has a 40-page paper in its two-year history. It also carries an inaugural ad from Johnnie Walker Black Label. Johnnie Walker will run advertising every Thursday and Friday until the end of the year, and will be the official sponsor of Private Equity-Venture Capital Friday, The Daily Deal's fifth weekly theme day section, debuting December 7. Johnnie Walker's campaign is appearing at a time when the company is participating in Windows of Hope Family Relief Fund.

About The Deal LLC
The Deal, LLC is the leading media company charting the deal economy for dealmakers worldwide. The company provides original news reporting, financial data and commentary on a full spectrum of global transactions and the personalities and politics of dealmakers behind the deals. Through The Daily Deal and TheDeal.com, as well as e-newsletters, newsletters and special reports, The Deal, LLC addresses the information needs of the deal community composed of corporate executives, entrepreneurs, institutional investors, financial intermediaries and advisers. Investors in The Deal, LLC, a privately held company, include majority owner U.S. Equity Partners, a private investment fund sponsored by Wasserstein & Co., LP, and Rustic Canyon Ventures, one of the largest venture capital funds in Southern California.